Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
175 hedge funds and large institutions have $356M invested in Antares Pharma, Inc. in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 50 reducing their positions, and 21 closing their positions.
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
5% more capital invested
Capital invested by funds: $339M → $356M (+$17.2M)
2% more funds holding
Funds holding: 171 → 175 (+4)
4% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 50
7% less call options, than puts
Call options by funds: $950K | Put options by funds: $1.02M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
+$10.3M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.17M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.35M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.89M |
| 5 |
SAM
Silvercrest Asset Management
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
-$13.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.1M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$2.11M |
| 5 |
BlackRock
New York
|
-$1.58M |
ATRS Hedge Fund Activity: Q2 2021 in Review
175 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2021, worth a combined $356M — up 5.1% from $339M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ATRS positions and 21 closed out — a net gain of 5 holders — while 52 added to existing stakes and 50 trimmed.
The largest buyer was First Wilshire Securities Management, opening a new position worth an estimated $10.3M. The largest seller was Centric Wealth Management, exiting entirely with an estimated $13.7M sold.
- 175 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2021, up from 171 in Q1 2021.
- Funds reported $356M of Antares Pharma, Inc. stock for Q2 2021, up 5.1% quarter-over-quarter.
- 26 funds opened new Antares Pharma, Inc. positions in Q2 2021 and 21 closed out, a net change of +5 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2021 was First Wilshire Securities Management, an estimated $10.3M added.
- The largest Antares Pharma, Inc. seller in Q2 2021 was Centric Wealth Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2021.